clinical trial · NCT07324616
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
Hepatic Impairment (HI)EDG-7500
brief summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.
started
Jan 26, 2026
primary completion
May 1, 2026
completion
May 1, 2026
last updated
Mar 9, 2026
official title
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Hepatic Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol